Nevertheless, unlike in the skin carcinogenesis model where the direction from initiation to promotion phase is non-interchangeable, in the PDA model, a Kras mutant can occur at least one month after the cessation of caerulein-induced inflammation and still reliably develop PDA [9]. The gene discussed is KRAS; the disease is Patent ductus arteriosus.